Bicycle Therapeutics Ltd
$ 5.62
3.31%
24 Feb - close price
- Market Cap 389,848,000 USD
- Current Price $ 5.62
- High / Low $ 5.78 / 5.45
- Stock P/E N/A
- Book Value 8.92
- EPS -3.62
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.35 %
- 52 Week High 11.62
- 52 Week Low 5.03
About
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Analyst Target Price
$18.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-08 | 2025-04-30 | 2025-02-18 | 2024-10-31 | 2024-08-06 | 2024-05-02 | 2024-02-20 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -0.85 | -1.14 | -0.88 | -0.8144 | -0.74 | -0.77 | -0.62 | -1.16 | -1.26 | -1.41 | -1.3 | -1.01 |
| Estimated EPS | -0.9708 | -0.94 | -0.8088 | -0.8536 | -0.78 | -1.1 | -1.24 | -1.23 | -1.17 | -1.29 | -1.07 | -1.06 |
| Surprise | 0.1208 | -0.2 | -0.0712 | 0.0392 | 0.04 | 0.33 | 0.62 | 0.07 | -0.09 | -0.12 | -0.23 | 0.05 |
| Surprise Percentage | 12.4433% | -21.2766% | -8.8032% | 4.5923% | 5.1282% | 30% | 50% | 5.6911% | -7.6923% | -9.3023% | -21.4953% | 4.717% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.9372 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCYC
2026-02-23 11:04:00
This article analyzes Bicycle Therapeutics Plc (NASDAQ: BCYC) using algorithmic entry frameworks. It highlights a strong near-term sentiment potentially challenging mid and long-term weakness, with an exceptional 55.0:1 risk-reward setup targeting a 21.2% gain against a 0.4% risk. The analysis includes institutional trading strategies for position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis.
2026-02-18 12:27:41
Bicycle Therapeutics (NASDAQ:BCYC) received an upgrade to "strong-buy" from Jefferies Financial Group, with a current "Moderate Buy" consensus rating and an average price target of $21.11, significantly higher than its current trading price of $5.23. Despite recent insider selling by the CEO and CFO, insiders still retain about 8.5% ownership. Institutional investors have generally increased their holdings, with Principal Financial Group and Acadian Asset Management notably boosting their stakes.
2026-02-17 10:28:06
Bicycle Therapeutics (NASDAQ:BCYC) is expected to report its Q4 2025 earnings before market open on Tuesday, February 24th, with analysts predicting a loss of ($1.00) per share. Insiders, including the CFO and CEO, recently sold shares, reducing their positions. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $20.20.
2026-02-14 21:27:41
Bicycle Therapeutics PLC (NASDAQ:BCYC) has received a consensus "Moderate Buy" rating from twelve analysts, with an average 12-month target price of $20.20. Despite this, the stock opened at $5.24, near its 52-week low, and has seen recent insider selling by its CFO and CEO. The company, which specializes in novel peptide therapeutics, has significant institutional ownership, with major investors like Westfield Capital Management and Armistice Capital increasing their stakes.
2026-02-12 09:58:18
This article analyzes Bicycle Therapeutics Plc (NASDAQ: BCYC) movements, noting a near-term neutral sentiment that suggests a pause in mid and long-term weakness. It highlights a significant 120.0:1 risk-reward setup targeting a 23.3% gain against a 0.2% risk, and outlines three AI-generated trading strategies for different risk profiles. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
2026-02-11 06:28:15
Bicycle Therapeutics (NASDAQ:BCYC) shares dropped 2.6% to $5.63, trading below major moving averages with a market capitalization of $390.6 million. Despite a "Moderate Buy" consensus rating and a $20.20 price target from analysts, insider selling by the CEO and CFO was reported, though institutional ownership remains high at 86.15%. Several institutional investors increased their stakes in the company recently.
